Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 22;78(6):1732–1744. doi: 10.1093/cid/ciae010

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Cumulative incidence of RSV-LRTD over 2 RSV seasons. Analysis includes cases reported from day 15 post–dose 1 until 31 March 2023 for participants who received dose 2 or until 30 September 2022 for those who did not receive dose 2. A, For the analysis of a single vaccine dose, participants who received 2 vaccine doses (RSV_revaccination group) contributed to RSV season 1 but were censored before dose 2 administration. B, For the analysis of the revaccination regimen, participants who received vaccine as dose 1 and placebo as dose 2 (RSV_1dose group) contributed to season 1 but were censored before dose 2 administration. Abbreviations: RSV, respiratory syncytial virus; RSV-LRTD, RSV-related lower respiratory tract disease confirmed by the adjudication committee; RSVPreF3 OA, RSV prefusion F protein–based vaccine.